Logo image of MRKR

MARKER THERAPEUTICS INC (MRKR) Stock Fundamental Analysis

NASDAQ:MRKR - US57055L2060 - Common Stock

1 USD
-0.26 (-20.63%)
Last: 8/26/2025, 8:00:01 PM
0.9529 USD
-0.05 (-4.71%)
Pre-Market: 8/27/2025, 6:18:40 AM
Fundamental Rating

3

Taking everything into account, MRKR scores 3 out of 10 in our fundamental rating. MRKR was compared to 547 industry peers in the Biotechnology industry. The financial health of MRKR is average, but there are quite some concerns on its profitability. MRKR is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

MRKR had negative earnings in the past year.
MRKR had a negative operating cash flow in the past year.
In the past 5 years MRKR always reported negative net income.
MRKR had a negative operating cash flow in each of the past 5 years.
MRKR Yearly Net Income VS EBIT VS OCF VS FCFMRKR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -75.23%, MRKR is doing worse than 64.90% of the companies in the same industry.
MRKR has a Return On Equity (-88.22%) which is in line with its industry peers.
Industry RankSector Rank
ROA -75.23%
ROE -88.22%
ROIC N/A
ROA(3y)-61.26%
ROA(5y)-61.64%
ROE(3y)-89.71%
ROE(5y)-93.87%
ROIC(3y)N/A
ROIC(5y)N/A
MRKR Yearly ROA, ROE, ROICMRKR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MRKR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRKR Yearly Profit, Operating, Gross MarginsMRKR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, MRKR has more shares outstanding
Compared to 5 years ago, MRKR has more shares outstanding
MRKR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MRKR Yearly Shares OutstandingMRKR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
MRKR Yearly Total Debt VS Total AssetsMRKR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -35.20, we must say that MRKR is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -35.20, MRKR is doing worse than 90.13% of the companies in the same industry.
There is no outstanding debt for MRKR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -35.2
ROIC/WACCN/A
WACCN/A
MRKR Yearly LT Debt VS Equity VS FCFMRKR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

MRKR has a Current Ratio of 6.79. This indicates that MRKR is financially healthy and has no problem in meeting its short term obligations.
MRKR has a Current ratio of 6.79. This is in the better half of the industry: MRKR outperforms 67.46% of its industry peers.
MRKR has a Quick Ratio of 6.79. This indicates that MRKR is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 6.79, MRKR is in the better half of the industry, outperforming 67.82% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.79
Quick Ratio 6.79
MRKR Yearly Current Assets VS Current LiabilitesMRKR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

7

3. Growth

3.1 Past

The earnings per share for MRKR have decreased strongly by -28.49% in the last year.
Looking at the last year, MRKR shows a very strong growth in Revenue. The Revenue has grown by 99.06%.
MRKR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 99.23% yearly.
EPS 1Y (TTM)-28.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16%
Revenue 1Y (TTM)99.06%
Revenue growth 3Y74.52%
Revenue growth 5Y99.23%
Sales Q2Q%-26.35%

3.2 Future

Based on estimates for the next years, MRKR will show a very strong growth in Earnings Per Share. The EPS will grow by 29.91% on average per year.
The Revenue is expected to grow by 95.82% on average over the next years. This is a very strong growth
EPS Next Y-79.63%
EPS Next 2Y-53.03%
EPS Next 3Y-8.8%
EPS Next 5Y29.91%
Revenue Next Year-69.91%
Revenue Next 2Y-40.96%
Revenue Next 3Y49.73%
Revenue Next 5Y95.82%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
MRKR Yearly Revenue VS EstimatesMRKR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
MRKR Yearly EPS VS EstimatesMRKR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100 -150 -200 -250

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MRKR. In the last year negative earnings were reported.
Also next year MRKR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRKR Price Earnings VS Forward Price EarningsMRKR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRKR Per share dataMRKR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

MRKR's earnings are expected to decrease with -8.80% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-53.03%
EPS Next 3Y-8.8%

More info and screens

0

5. Dividend

5.1 Amount

MRKR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MARKER THERAPEUTICS INC

NASDAQ:MRKR (8/26/2025, 8:00:01 PM)

Premarket: 0.9529 -0.05 (-4.71%)

1

-0.26 (-20.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-12 2025-11-12
Inst Owners36.11%
Inst Owner Change-14.23%
Ins Owners2.42%
Ins Owner Change0%
Market Cap12.94M
Analysts84.44
Price Target8.33 (733%)
Short Float %3.97%
Short Ratio0.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-29.77%
Min EPS beat(2)-87.59%
Max EPS beat(2)28.04%
EPS beat(4)3
Avg EPS beat(4)4.52%
Min EPS beat(4)-87.59%
Max EPS beat(4)43%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-38.06%
Min Revenue beat(2)-44.56%
Max Revenue beat(2)-31.57%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-24.9%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.94%
EPS NY rev (1m)11.94%
EPS NY rev (3m)19.52%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)44.6%
Revenue NY rev (1m)-7.23%
Revenue NY rev (3m)-22.32%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.27
P/FCF N/A
P/OCF N/A
P/B 0.89
P/tB 0.89
EV/EBITDA N/A
EPS(TTM)-1.33
EYN/A
EPS(NY)-2.81
Fwd EYN/A
FCF(TTM)-0.97
FCFYN/A
OCF(TTM)-0.97
OCFYN/A
SpS0.44
BVpS1.12
TBVpS1.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -75.23%
ROE -88.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.26%
ROA(5y)-61.64%
ROE(3y)-89.71%
ROE(5y)-93.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.79
Quick Ratio 6.79
Altman-Z -35.2
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-28.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16%
EPS Next Y-79.63%
EPS Next 2Y-53.03%
EPS Next 3Y-8.8%
EPS Next 5Y29.91%
Revenue 1Y (TTM)99.06%
Revenue growth 3Y74.52%
Revenue growth 5Y99.23%
Sales Q2Q%-26.35%
Revenue Next Year-69.91%
Revenue Next 2Y-40.96%
Revenue Next 3Y49.73%
Revenue Next 5Y95.82%
EBIT growth 1Y0.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3367.51%
EBIT Next 3Y-137.86%
EBIT Next 5Y202.77%
FCF growth 1Y45.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.06%
OCF growth 3YN/A
OCF growth 5YN/A